Jul 10 2006
CAS Medical Systems has announced that it has been awarded two United States Patents for technology used in its Fore-Sight Cerebral Oximeter, which is scheduled for commercial release in late 2006.
The patents represent several years of research and development focused on bringing to market a non-invasive, commercially viable technology that allows clinicians to monitor absolute levels of oxygen saturation in the brain. The new patents (U.S. Patent 7,047,054 and U.S. Patent 7,072,701) cover aspects of the FORE-SIGHT patient sensor design and laser safety system, as well as the algorithm method used by the FORE-SIGHT device to allow for an absolute measurement.
"Our research and development team has made great strides in the development of this device, and the receipt of two more patents for technology used in FORE-SIGHT is an important milestone and highlights our strong IP position," stated Louis P. Scheps, President and CEO of CAS Medical. "Our goal is to continue to pursue the issuance of patents to enable us to maximize the value of the innovative technology used in this compelling device. We believe that our recent achievements, in combination with the launch of the FORE-SIGHT product at the end of this year, will continue to propel the company's future growth."
http://www.casmed.com
Research reveals only a few brain regions remain untouched by transition to motherhood